Sign in Subscribe
Genetic research

Novel Cancer Gene Therapy Strategy Using Mesenchymal Stem Cells Shows Promise

Strategic Insights

— 2 min read

Researchers at Sungkyunkwan University School of Medicine in South Korea have developed a novel therapeutic strategy for lung cancer brain metastases using genetically engineered mesenchymal stem cells. The study, published in Cancer Research Communications, demonstrates the effectiveness of using autologous Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) as vehicles for dual-agent gene therapy across the blood-brain barrier. The WJ-MSCs were engineered to coexpress soluble TRAIL (sTRAIL) and the prodrug-activating enzyme carboxylesterase 1 (CES1), which enabled the activation of CPT-11 into SN-38 and induced apoptosis through death receptor signaling.

Key Takeaways:

  • The study demonstrates the efficacy of using WJ-MSCs as a nonviral, transient gene delivery platform for dual-action gene therapy in lung cancer brain metastases.
  • The combined use of CES1 and sTRAIL enables precise tumor targeting and drug activation, offering a promising avenue for personalized, stem cell-based treatment strategies.
  • The dual-action strategy significantly reduced brain tumor burden with minimal toxicity, demonstrating strong therapeutic potential.
  • The study established a nonviral, transient gene delivery platform using autologous WJ-MSCs for dual-action gene therapy in lung cancer brain metastases.
  • The use of WJ-MSCs expressing sTRAIL and CES1 showed strong therapeutic potential, with minimal off-target effects and favorable safety profiles.
  • The study concluded that the combined use of CES1 and sTRAIL and enables precise tumor targeting and drug activation, offering a promising avenue for personalized, stem cell-based treatment strategies to improve outcomes in patients with brain metastatic lung cancer.

Statistics:

  • The study used bioluminescent imaging to assess therapeutic efficacy in subcutaneous and intracerebral lung cancer xenograft models.
  • The results showed that combination therapy with WJ-MSCs-CES1.sTRAIL and CPT-11 significantly suppressed tumor growth in lung cancer brain metastasis models compared with control groups.
  • The WJ-MSCs were transiently engineered using lipid nanoparticle technology to coexpress soluble TRAIL (sTRAIL) and the prodrug-activating enzyme carboxylesterase 1 (CES1).
  • The study demonstrated the therapeutic potential of using WJ-MSCs expressing sTRAIL and CES1 in lung cancer brain metastatic lesions, with minimal toxicity and favorable safety profiles.

Sources:

  • Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions. Cancer Research Communications, 2025;5(9):1552-1565.
  • NewsRx. New Cancer Gene Therapy Study Findings Recently Were Reported by Researchers at Sungkyunkwan University School of Medicine (Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain ...). Biotech Week. September 24, 2025; p 45.

Read more